Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azetidine SCHEMBL17938012 | 0.97 | CXCR4 (0.33) | CXCR4SMN1; SMN2ALDH1A1 | |
| Pyrrolidine SCHEMBL28552039 | 0.94 | ALDH1A1 (0.47) | CXCR4SMN1; SMN2ALDH1A1 | |
| Piperidine SCHEMBL3261905 | 0.91 | ALDH1A1 (0.53) | CXCR4SMN1; SMN2ALDH1A1 | |
| Azepane SCHEMBL28558375 | 0.91 | ALDH1A1 (0.53) | CXCR4SMN1; SMN2ALDH1A1 | |
| Aziridine SCHEMBL29082712 | 0.89 | HIF1A (0.36) | — | |
| Piperazine SCHEMBL28595975 | 0.86 | HIF1A (0.43) | CXCR4SMN1; SMN2 | |
| Piperidine SCHEMBL28074884 | 0.84 | ALDH1A1 (0.45) | CXCR4SMN1; SMN2ALDH1A1 | |
| Cyclohexane SCHEMBL8471239 | 0.81 | ADH1C (0.32) | ALDH1A1 | |
| SCHEMBL8437985 | 0.80 | ALDH1A1 (0.36) | ALDH1A1 | |
| Fluoride SCHEMBL6463523 | 0.77 | ADH1C (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045520-B2 | Synthesis of purine nucleosides | GILEAD PHARMASSET LLC (US) | 2015-06-02 | — | — | US | disclosed |
| US-8716263-B2 | Synthesis of purine nucleosides | GILEAD PHARMASSET LLC (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2671888-A1 | 3',5'-cyclic nucleoside phosphate analogues | Gilead Pharmasset LLC (US) | 2013-12-11 | — | — | EP | disclosed |
| US-20120316327-A1 | SYNTHESIS OF PURINE NUCLEOSIDES | GILEAD PHARMASSET LLC (US) | 2012-12-13 | — | — | US | disclosed |
| EP-2376515-A1 | Synthesis of purine nucleosides | Pharmasset, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20100279973-A1 | SYNTHESIS OF PURINE NUCLEOSIDES | PHARMASSET, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| WO-2010075554-A1 | SYNTHESIS OF PURINE NUCLEOSIDES | PHARMASSET, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279973-A1 | SYNTHESIS OF PURINE NUCLEOSIDES | PNP, NUDT1, TYMP | CXCR4 818/4885SMN1; SMN2 2741/4885ALDH1A1 2131/4885 |
| US-20120316327-A1 | SYNTHESIS OF PURINE NUCLEOSIDES | PNP, NUDT1, TYMP | CXCR4 818/4885SMN1; SMN2 2741/4885ALDH1A1 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.